

Published in final edited form as:

*Org Lett.* 2014 February 7; 16(3): 864–867. doi:10.1021/ol403631k.

## Direct, Catalytic and Regioselective Synthesis of 2-Alkyl, Aryl, and Alkenyl-Substituted *N*-Heterocycles from *N*-Oxides

Oleg V. Larionov\*, David Stephens, Adelphe Mfuh, and Gabriel Chavez

Department of Chemistry, University of Texas at San Antonio, One UTSA Circle, San Antonio, Texas 78249, United States

### Abstract

A one-step transformation of heterocyclic *N*-oxides to 2-alkyl, aryl, and alkenyl-substituted *N*-heterocycles is described. The success of this broad-scope methodology hinges on the combination of copper catalysis and activation by lithium fluoride or magnesium chloride. The utility of this method for the late-stage modification of complex *N*-heterocycles is exemplified by facile syntheses of new structural analogs of several antimalarial, antimicrobial and fungicidal agents.

Substituted *N*-heterocycles are important structural motifs of bio-active compounds and advanced materials.<sup>1</sup> Hence, methods that allow for regioselective construction of C–C bonds to *N*-heterocycles have attracted continuous attention.<sup>2</sup> In particular, introduction of substituents in the C2-position of pyridines, quinolines and related six-membered nitrogenous heterocycles is an important strategy in heterocyclic synthesis that represents a significant synthetic challenge.<sup>3</sup> One of the most commonly used strategies is based on transition metal-catalyzed coupling reactions of organometallic reagents with 2-haloazines,<sup>4</sup> which are prepared from the corresponding *N*-oxides<sup>5</sup> (Scheme 1). However, despite its widespread use, this route has significant drawbacks. The synthesis of 2-haloazines from the *N*-oxides is low-yielding due to poor regioselectivity. In addition, although significant progress has been achieved in the development of catalytic coupling reactions of 2-haloazines, most of the methods focus on construction of aryl-heteroaryl bonds. A more recent strategy that has been developed by Fagnou and other groups entails Pd-catalyzed CH-functionalization of the heterocyclic *N*-oxides.<sup>6</sup> However, a reduction of the N–O bond is required to produce the corresponding 2-substituted *N*-heterocycles, and excess *N*-oxide is needed to achieve good yields. It would be, therefore, advantageous to devise a direct one-step method for regioselective conversion of heterocyclic *N*-oxides to 2-substituted *N*-heterocycles. We herein report a coupling reaction of heterocyclic *N*-oxides with Grignard reagents that directly affords 2-aryl, alkyl and alkenyl-substituted *N*-heterocycles regioselectively and in good to excellent yield.

Grignard reagents have previously been known to react with heterocyclic *N*-oxides to give predominantly, depending on reaction conditions and the structure of the heterocyclic core,

\*Corresponding Author: oleg.larionov@utsa.edu.

Supporting Information

Experimental procedures, as well as spectral data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

variable ratios of addition and ring-opening products (Scheme 1). Based on the early work by Kellogg, Shiess<sup>7</sup> and Kato,<sup>8</sup> Almqvist and Olsson,<sup>9</sup> as well as Duan<sup>10</sup> have significantly improved the versatility of the method, and showed that both products can subsequently be converted to 2-alkyl and aryl-substituted *N*-heterocycles on treatment with dehydrating reagents in a stepwise fashion.

We began our study by examining the reaction between quinoline *N*-oxide and isopropylmagnesium chloride (Table 1) in diethyl ether. While formation of product **3** was not observed upon reacting **1** and **2** in the absence of a catalyst, a yield of 53% was achieved in the presence of 10 mol% of copper(I) chloride. Iron(II) chloride was less effective, leading to complex reaction mixtures and a 36% yield of **3**. Attempts to augment the activity of the copper and iron catalysts by using phosphine, NHC and amine ligands were not successful. Similarly, cobalt and nickel exhibited no appreciable catalytic activity (entries 5–7). Further experiments showed that copper(I) chloride was superior to other copper(I) and copper(II) salts (e.g. entries 8 and 9).

Solvents were found to have a notable effect on the reaction efficiency. Ethereal solvents (diethyl ether and methyl *tert*-butyl ether) proved to be the optimal reaction media, while formation of substantial amounts of side-products was observed in tetrahydro-furan (THF), toluene (entries 10 and 11) and other non-ethereal solvents. Ambient temperature (23 °C) was found to be optimal, while diminished yields of coupling product **3** were observed at lower (–20 and 0 °C) and higher (50 °C, in a sealed vessel) temperatures (entries 13–14).

In an effort to improve the yield, we then turned our attention to additives, since it is known that the reactivity of organomagnesium<sup>11</sup> and organocopper<sup>12</sup> species can be modulated by Lewis acids and bases.

Encouragingly, addition of LiCl improved the yield to 67%. At the same time, zinc bromide and *N,N,N',N'*-tetramethyl-ethylenediamine (tmeda) completely suppressed the coupling (entries 16 and 17). Surprisingly, when the reaction was run in the presence of magnesium chloride, a clean conversion of *N*-oxide **1** into product **3** took place (entry 18, 95% yield). It is interesting that other magnesium salts (e.g. fluoride, entry 19) were much less effective. On the other hand, lithium fluoride exhibited comparable efficiency to magnesium chloride (entry 20).

After completion of the optimization study we set out to explore the scope of the novel method with other Grignard reagents (16 reagents) and heterocyclic *N*-oxides (12 substrates) (Figure 1).

The reaction generally shows a broad scope for both counterparts. Thus, both primary and secondary alkylmagnesium halides proved to be suitable nucleophiles for the reaction with substituted quinoline, pyridine and isoquinoline *N*-oxides giving rise to the corresponding products in a highly regioselective fashion.

Similarly, arylmagnesium halides afforded the desired products in good yields, e.g. *o*-tolyl group can be installed in 61% yield. 2-Propenylmagnesium bromide also proved to be a

suitable nucleophile. With respect to the *N*-oxide counterparts, quinoline, isoquinoline, pyridine, phenanthridine, pyrazine and quinoxaline *N*-oxides are viable substrates.

Halogenated substrates undergo chemoselective reaction at C2-position with Grignard reagents under these conditions, including 4-chloroquinoline that is known to be prone to facile nucleophilic displacement of the 4-chloro group.<sup>13</sup> Hydroxy group is also well tolerated, provided that an additional equivalent of a Grignard reagent is added. The reaction has been successfully carried out on preparative scale (e.g. 3 g 2-phenylquinoline from **1** and phenylmagnesium chloride) with a 94% yield.

The new method has been used for the synthesis of several derivatives of biologically relevant heterocycles. 2'-Isopropyl and 2'-phenyl substituted dihydrocinchonidine derivatives **6a,b** have been prepared from *N*-oxide **7** in 65 and 37% yields (Scheme 2).

Similarly, antimicrobial drug chlorquinaldol **8a** (63%) and the 2-cyclohexyl analog **8b** (84%) have been accessed from *N*-oxide **9a**, as well as 2-methyl and 2-(*m*-methoxyphenyl) derivatives **8c,d** of an antimicrobial drug cloxyquin from *N*-oxide **9b**. In addition, 2-phenyl derivative of selective agrochemical fungicide quinoxifen (Quintec™) **10** has been prepared in 68% yield.

The chemoselective preference for the C2-addition in 4-chloroquinoline *N*-oxides has been exploited for a regioselective synthesis of new structural analogs of antimalarial drugs amodiaquine and chloroquine (Scheme 3). Both 4-aminoquinolines have long been considered as the most important drugs for the treatment and prophylaxis of malaria.<sup>14</sup> However, the emergence of widespread parasite resistance to these drugs in every region, where *P. falciparum* is prevalent, has spurred interest in new 4-aminoquinolines with improved pharmacological profiles.<sup>15</sup> In addition, chloroquine has recently demonstrated promising anti-tumor,<sup>16</sup> antirheumatic<sup>17</sup> and antiviral activities.<sup>18</sup>

The amodiaquine derivatives **11a,b** were prepared in 42 and 77% combined yields from *N*-oxide **12** in two steps. The copper-catalyzed reaction with a Grignard reagent and magnesium chloride was followed by a condensation of quinolines **13** with aniline **14**. Similarly, chloroquine derivatives **15a,b** that bear 2-cyclohexyl and 2-ethyl groups, have been synthesized in two steps by way of converting *N*-oxide **12** into quinolines **16**, followed by a samarium triflate-catalyzed displacement reaction with amine **17**.

In conclusion, we have developed a direct catalytic synthesis of 2-substituted nitrogenous heterocycles from Grignard reagents and *N*-oxides. Magnesium chloride and lithium fluoride have been identified as additives that drastically improve the chemoselectivity of the reaction. The reported transformation of heterocyclic *N*-oxides to 2-substituted heterocycles can be used to access heterocyclic scaffolds of practical synthetic and medicinal value as exemplified by facile late-stage modification of several antimalarial, antimicrobial and fungicidal agents.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


## Acknowledgments

We thank the Welch Foundation (AX-1788), the Max and Minnie Tomerlin Voelcker Fund and the University of Texas at San Antonio for financial support. Mass spectroscopic analysis was supported by a grant from the National Institute on Minority Health and Health Disparities (G12MD007591).

## References


- (a) Horton DA, Bourne GT, Smythe ML. *Chem Rev.* 2003; 103:893–930. [PubMed: 12630855] (b) Vieth M, Siegel MG, Higgs RE, Watson IA, Robertson DH, Savin KA, Durst GL, Hipskind PA. *J Med Chem.* 2004; 47:224–232. [PubMed: 14695836] (c) Welsch ME, Snyder SA, Stockwell BR. *Curr Opin Chem Biol.* 2010; 14:347–361. [PubMed: 20303320]
- (a) Yokoyama A, Nishiyama I, Yoshizawa A. *Ferroelectrics.* 1993; 148:139.(b) Skrypink YG, Doroshenko TF. *Mater Sci.* 1996; 32:537.(c) Tsutsumi H, Okada K, Oishi T. *Electrochim Acta.* 1996; 41:2657.(d) Bangcuayo CG, Rampey-Vaughn ME, Quan LT, Angel SM, Smith MD, Bunz UHF. *Macromolecules.* 2002; 35:1563.(e) Vetrichelvan M, Valiyaveetil S. *Chem Eur J.* 2005; 11:5889. [PubMed: 15973745] (e) Ji X, Huang H, Li Y, Chen H, Jiang H. *Angew Chem Int Ed.* 2012; 51:7292–7296.(f) Hyodo I, Tobisu M, Chatani N. *Chem Asian J.* 2012; 7:1357–1365. [PubMed: 22442050] (g) Zhuo FF, Xie WW, Yang YX, Zhang L, Wang P, Yuan R, Da CS. *J Org Chem.* 2013; 78:3243–3249. [PubMed: 23464705] (h) Nakao Y, Kanyiva KS, Hiyama T. *J Am Chem Soc.* 2008; 130:2448. [PubMed: 18247621]
- (a) Fujiwara Y, Dixon JA, O'Hara F, Funder ED, Dixon DD, Rodriguez RA, Baxter RD, Herle B, Sach N, Collins MR, Ishihara Y, Baran PS. *Nature.* 2012; 492:95–99. [PubMed: 23201691] (b) Liu B, Huang Y, Lan J, Songa F, You J. *Chem Sci.* 2013; 4:2163–2167.(c) Yao B, Song RJ, Liu Y, Xie YX, Li JH, Wang MK, Tang RY, Zhang XJ, Deng CL. *Adv Synth Catal.* 2012; 354:1890–1896.(d) Ren X, Wen P, Shi X, Wang Y, Li J, Yang S, Yan H, Huang G. *Org Lett.* 2013; 15:5194–5197. [PubMed: 24073790]
- (a) Bonnet V, Mongin F, Trecourt F, Queguiner G, Knochel P. *Tetrahedron.* 2002; 58:4429–4438. (b) Lutzen A, Hapke M. *Eur J Org Chem.* 2002; 14:2292–2297.(c) Slagt VF, de Vries AHM, de Vries JG, Kellogg RM. *Org Proc Res Dev.* 2010; 14:30–47.(d) Iglesias MJ, Prieto A, Nicasio MC. *Org Lett.* 2012; 14:4318–4321. [PubMed: 22894704] (e) Kuzmina OM, Steib AK, Flubacher D, Knochel P. *Org Lett.* 2012; 14:4818–4821. [PubMed: 22966964] (f) Kuzmina OM, Steib AK, Markiewicz JT, Flubacher D, Knochel P. *Angew Chem Int Ed.* 2013; 52:4945–4949.(g) Steib AK, Kuzmina OM, Fernandez S, Flubacher D, Knochel P. *J Am Chem Soc.* 2013; 135:15346–15349. [PubMed: 24053764]
- (a) Ash ML, Pew RG. *J Heterocyclic Chem.* 1981; 18:939–940.(b) Mittelbach M. *Synthesis.* 1988:479–480.(c) Singh B, Leshner GY, Pennock PO. *J Heterocyclic Chem.* 1990; 27:1841–1842.(d) Hurst DT. *Adv Heterocyclic Chem.* 1993; 58:227–269.(e) Constable EC, Seddon KR. *Tetrahedron.* 1983; 39:291–295.(f) Koenig T, Wiczorek JS. *J Org Chem.* 1968; 33:1530–1532.(g) Vozza J. *J Org Chem.* 1962; 27:3856–3860.(h) Yamanaka H, Arak T, Sakamoto T. *Chem Pharm Bull.* 1988; 36:2244–2247.(i) Wengryniuk SE, Weickgenannt A, Reiher C, Strotman NA, Chen K, Eastgate MD, Baran PS. *Org Lett.* 2013; 15:792–795. [PubMed: 23350852]
- (a) Campeau LC, Rousseaux S, Fagnou K. *J Am Chem Soc.* 2005; 127:18020. [PubMed: 16366550] (b) Leclerc JP, Fagnou K. *Angew Chem, Int Ed.* 2006; 45:7781–7786.(c) Kanyiva KS, Nakao Y, Hiyama T. *Angew Chem, Int Ed.* 2007; 46:8872.(d) Cho SH, Hwang SJ, Chang S. *J Am Chem Soc.* 2008; 130:9254–9256. [PubMed: 18582040] (e) Wu J, Cui X, Chen L, Jiang G, Wu Y. *J Am Chem Soc.* 2009; 131:13888–13889. [PubMed: 19746974] (f) Xiao B, Liu ZJ, Liu L, Fu Y. *J Am Chem Soc.* 2013; 135:616–619. [PubMed: 23282325]
- (a) Kellogg RM, Van Bergen TJ. *J Org Chem.* 1971; 36:1705–1708.(b) Schiess P, Ringele P. *Tetrahedron Lett.* 1972; 311–312
- Kato T, Yamanaka H. *J Org Chem.* 1965; 30:910–913. [PubMed: 14285684]
- (a) Hussain M, Banchelin TSL, Andersson H, Olsson R, Almqvist F. *Org Lett.* 2013; 15:54–57. [PubMed: 23256529] (b) Andersson H, Olsson R, Almqvist F. *Org Biomol Chem.* 2011; 9:337–346. [PubMed: 21076758] (c) Andersson H, Banchelin TSL, Das S, Gustafsson M, Olsson R, Almqvist F. *Org Lett.* 2010; 12:284–286. [PubMed: 20000607] (d) Andersson H, Banchelin TSL, Das S, Olsson R, Almqvist F. *Chem Commun.* 2010; 46:3384–3386.(e) Andersson H, Gustafsson

- M, Bostrom D, Olsson R, Almqvist F. *Angew Chem Intl Ed.* 2009; 48:3288–3291.(f) Andersson H, Wang X, Bjorklund M, Olsson R, Almqvist F. *Tetrahedron Lett.* 2007; 48:6941–6944.(g) Andersson H, Almqvist F, Olsson R. *Org Lett.* 2007; 9:1335–1337. [PubMed: 17328555]
10. (a) Zhang S, Liao LY, Zhang F, Duan XF. *J Org Chem.* 2013; 78:2720–2725. [PubMed: 23390982] (b) Zhang F, Zhang S, Duan XF. *Org Lett.* 2012; 14:5618–5620. [PubMed: 23078022] (c) Zhang F, Duan XF. *Org Lett.* 2011; 13:6102–6105. [PubMed: 22032274]
11. (a) Farkas JJ, Stoudt SJ, Hanawalt EM, Pajerski AD, Richey HGJ. *Organometallics.* 2004; 23:423–427.(b) Hanawalt EM, Farkas JJ, Richey HGJ. *Organometallics.* 2004; 23:416–422.(c) Westerhausen M. *Dalton Trans.* 2006; 40:4755–4768. [PubMed: 17033700]
12. (a) Kleijn H, Elsevier CJ, Westmijze H, Meijer J, Vermeer P. *Tetrahedron Lett.* 1979:3101–3102. (b) Marfat A, McGuirk PR, Helquist P. *J Org Chem.* 1979; 44:3888–3901.(c) Davies RP. *Coord Chem Rev.* 2011; 255:11–12.
13. (a) Pino P, Piccolo O, Straub B, Consiglio G, Dich CT. *Helv Chim Acta.* 1982; 65:2102–2109.(b) Wendeborn S, Winkler T, Foisy I. *Tetrahedron Lett.* 2000; 41:6387–6391.(c) Matsumoto K, Kannami M, Inokuchi D, Kurata H, Kawase T, Oda M. *Org Lett.* 2007; 9:2903–2906. [PubMed: 17602492]
14. O'Neill, PM.; Barton, VE.; Ward, SA.; Chadwick, J. *Treatment and Prevention of Malaria.* Staines, HM.; Krishna, S., editors. Springer; Basel: 2012. p. 19-44.
15. (a) Winstanley PA, Ward SA, Snow RW. *Microb Infect.* 2002; 4:157–164.(b) Martin RE, Marchetti RV, Cowan AI, Howitt SM, Bröer S, Kirk K. *Science.* 2009; 325:1680–1682. [PubMed: 19779197]
16. Solomon VR, Lee H. *Eur J Pharmacol.* 2009; 625:220–233. [PubMed: 19836374]
17. Augustijns P, Geusens P, Verbeke N. *Eur J Clin Pharmacol.* 1992; 42:429–433. [PubMed: 1307690]
18. Savarino A, Di TL, Donatelli I, Cauda R, Cassone A. *Lancet Infect Dis.* 2006; 6:67–69. [PubMed: 16439323]




**Figure 1. Scope of the Azine N-Oxides and Grignard Reagents.<sup>a</sup>**

<sup>a</sup> Reaction conditions: **4** (0.17–1.3 mmol),  $\text{RMgX}$  (1.5–4 equiv),  $\text{MgCl}_2$  or  $\text{LiF}$  (1.5–4 equiv), catalyst (5–10 mol %),  $\text{Et}_2\text{O}$  ( $c=0.2$  M), at 23 °C under Ar for 12 h. <sup>b</sup>  $\text{RMgCl}$  was used as a nucleophile. <sup>c</sup> The reaction was run with  $\text{RMgBr}$ . <sup>d</sup>  $\text{RMgI}$  was used. <sup>e</sup> The reaction was run with  $\text{LiF}$  as an additive.

Reactions of Grignard Reagents with Heterocyclic *N*-Oxides


Scheme 1.

Methods of synthesis of 2-substituted *N*-heterocycles from *N*-oxides.

**Scheme 2.**

Synthesis of 2-substituted derivatives of cinchonidine, chlorquinaldol, cloxyquin and quinoxifen.






Scheme 3.

Preparation of 2-substituted derivatives of amodiaquine and chloroquine.

Table 1

Optimization of the Reaction Conditions.<sup>a</sup>


entry	catalyst	additive <sup>b</sup>	solvent	temp (°C)	yield %
1	–	–	Et <sub>2</sub> O	23	0
2	CuCl	–	Et <sub>2</sub> O	23	53
3	FeCl <sub>2</sub>	–	Et <sub>2</sub> O	23	36
4 <sup>c</sup>	FeCl <sub>2</sub> /SIMes	–	THF	23	0
5	CoCl <sub>2</sub>	–	Et <sub>2</sub> O	23	6
6	Ni(PPh <sub>3</sub> ) <sub>2</sub> Cl <sub>2</sub>	–	THF	23	3
7	NiCl <sub>2</sub> -dme	–	Et <sub>2</sub> O	23	0
8	CuCl <sub>2</sub>	–	Et <sub>2</sub> O	23	17
9	CuBr	–	Et <sub>2</sub> O	23	21
10	CuCl	–	THF	23	45
11	CuCl	–	PhMe	23	38
12	CuCl	–	Et <sub>2</sub> O	0	44
13	CuCl	–	Et <sub>2</sub> O	–20	25
14	CuCl	–	Et <sub>2</sub> O	50	42
15	CuCl	LiCl	Et <sub>2</sub> O	23	67
16	CuCl	ZnBr <sub>2</sub>	Et <sub>2</sub> O	23	0
17	CuCl	tmeda	Et <sub>2</sub> O	23	2
18	<b>CuCl</b>	<b>MgCl<sub>2</sub></b>	<b>Et<sub>2</sub>O</b>	23	<b>95</b>
19	CuCl	MgF <sub>2</sub>	Et <sub>2</sub> O	23	37
20	<b>CuCl</b>	<b>LiF</b>	<b>Et<sub>2</sub>O</b>	23	<b>96</b>

<sup>a</sup> Reaction conditions: **1** (0.17 mmol), **2** (1.5 equiv), catalyst (10 mol %), in the solvent (1 mL) under Ar for 12 h.

<sup>b</sup> 1.5 equiv

<sup>c</sup> SIMes = 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene.